Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01183897 · ClinicalTrials.gov registry record · Phase 2
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01183897: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01183897 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01183897, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to see find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.
Interventions
- BIOLOGICAL 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-08-12 |
| Est. Completion | 2018-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01183897
The ClinicalTrials.gov registry entry for NCT01183897 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic is the first listed.
NCT01183897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01183897 about?
NCT01183897 is a clinical study titled "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow". The purpose of this study is to see find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.
What is the current status of trial NCT01183897?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2010-08-12. Estimated completion is 2018-09-25.
What interventions are being tested in trial NCT01183897?
The interventions under investigation include: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic (BIOLOGICAL).
Who is sponsoring clinical trial NCT01183897?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.